relapsed refractory multiple myeloma

FLORHAM PARK, N.J., July 15, 2026 Cellectar Biosciences announced the publication of results from its Phase 1 dose-escalation study...

Beerse, Belgium — March 10, 2026 Global healthcare company Johnson & Johnson has announced the submission of a Type...